Vascular Flow Technologies have presented study results at the 41st Annual VEITH Symposium on Vascular and Endovascular Issues in New York, showing a 30% increase in one-year success for infrainguinal vascular bypass surgery in patients who received a Spiral Flow™ Graft compared to those who received a standard polytetrafluoroethylene (PTFE) graft.
VIVA Physicians, Inc. announced that 4-year results from a prospective, single-arm, multicenter trial conducted at 26 sites in the United States to evaluate the Endurant stent graft system (Medtronic, Inc.) for the treatment of abdominal aortic aneurysms (AAAs) were presented by Edward Woo, MD, during a late-breaking trials session at the VIVA 2014: Vascular InterVentional Advances meeting in Las Vegas, Nevada.
VIVA Physicians, Inc. announced that Michael Dake, MD, presented the trial plan and reported preliminary findings from the Gore TAG Thoracic Branch Zone 2 Feasibility Study during a late-breaking trials session at the VIVA 2014: Vascular InterVentional Advances meeting in Las Vegas, Nevada.
Hansen Medical, Inc. announced that the company´s Magellan 6-F robotic catheter has received European CE Mark approval for use in the peripheral vasculature. This allows the company to market the Magellan 6-F device in Europe and other countries that recognize the CE Mark. In February 2014, the company announced US Food and Drug Administration 510(k) clearance for the Magellan 6-F robotic catheter, which is commercially available in the United States.
TriVascular Technologies, Inc. announced the commencement of enrollment in the LIFE Study, a multicenter postmarket registry designed to evaluate the Ovation Prime abdominal stent graft system in the treatment of patients with abdominal aortic aneurysms (AAA) using a fast-track protocol for endovascular aneurysm repair (EVAR).
Bolton Medical announced the initiation of the Regeneration clinical trial that will assess the safety and effectiveness of the company’s Relay Pro and Relay NBS Pro thoracic stent graft systems in patients with thoracic aortic pathologies. The study results will support the company´s application for CE Mark approval of the Relay Pro devices.
TriVascular announced that the US Food and Drug Administration has approved its CustomSeal technology for the Ovation Prime endograft system. The customized sealing technology enables faster procedure times, preserves the aortic neck, and provides an optimized seal that is tailored to each patient´s specific anatomy, stated the company.
Julie Brittenden, MD, et al published findings from a randomized trial comparing treatments for varicose veins in the New England Journal of Medicine (2014;371:1218–1227). The background of the study is that ultrasound-guided foam sclerotherapy and endovenous laser ablation are widely used alternatives to surgery for the treatment of varicose veins, but their comparative effectiveness and safety remain uncertain, noted the investigators. The study was sponsored by the University of Aberdeen in Scotland, United Kingdom.
The national principal investigator of the ATTRACT study shares his insights on DVT treatment, regulatory hindrances in the venous space, and the progression of interventional radiology fellowships.
Venous return is attained through a complex interaction of valves, muscle pumps, and pressure gradients and is greatly influenced by position. In the upright position, gravity is counteracted by the valve-pump system; however, in the supine position, hydrostatic pressure disappears, and pressure gradients effect flow. Duplex ultrasound (DUS) technology uses sound to provide relatively limited information about this complex physiologic system. The physician must therefore rely mostly on clinical skills when treating patients with venous disease.
Varicose veins are largely treated by changing the circulatory pattern created by the underlying valvular failure. This frequently involves disconnecting superficial and deep connections that have incompetent valves to stop the flow from high-pressure deep veins back into low-pressure superficial veins and then ablating the damaged superficial veins (varicosities) either surgically, chemically, or thermally. Because there are numerous connections from superficial to deep veins (perforators) that could potentially fail,1 recurrence should be less of a surprise than the lack thereof. Good treatment necessitates the identification of these abnormal connections, which requires imaging that both identifies the perforator and demonstrates the abnormal flow. The use of duplex ultrasound has greatly improved the accuracy of identifying the problematic perforator, the most common being the saphenofemoral junction.
Determining therapeutic protocol for acute and chronic DVT.
Clarification of questions arising about the use of a new code for venous embolization, 37241.
Michael R. Jaff, DO, discusses the differences between the arterial and venous stent landscapes and what the future might hold.
A study that examined the incidence of cerebral microembolization and silent cerebral infarction after thoracic endovascular aneurysm repair (TEVAR) concluded that two-thirds of patients undergoing MRI had evidence of silent cerebral infarction—a previously unrecognised burden.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos